Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, April 2006, p. 1522-1524, Vol. 50, No. 4
0066-4804/06/$08.00+0 doi:10.1128/AAC.50.4.1522-1524.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Department of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada
Received 1 November 2005/ Returned for modification 21 December 2005/ Accepted 7 February 2006
|
|
|---|
|
|
|---|
Model membrane studies have shown that this peptide interacts preferentially with negatively charged membranes and induces lipid flip-flop between membrane leaflets at concentrations that show little or no disturbance to bilayer integrity (9). Polyphemusin I is able to translocate membrane bilayers and gain access to the interior of vesicles (6, 9) and has recently been shown to induce negative membrane curvature strain (5), a property that may be involved in the translocation process. Indeed, peptides from other structural classes, including buforin II (4) and pyrrhocoricin (2), have also been shown to translocate across membranes and are proposed to act on intracellular targets in eliciting their antimicrobial activity.
To further characterize the antibacterial action of the polyphemusins, it was of significant interest to determine where these peptides localize on or within the bacterium following treatment. While translocation has been inferred from model membrane assays, this finding has yet to be confirmed by whole-cell assays. To accomplish this, we synthesized a polyphemusin I analogue with a single C-terminal biotin label. This peptide, PM1-biotin, was then characterized and compared to the native polyphemusin I. To determine peptide localization, fluorescence and confocal microscopy were performed after treatment of a wild-type Escherichia coli strain with PM1-biotin. The data clearly indicate that polyphemusin translocated into E. coli with only modest cytoplasmic membrane disruption and caused disorganization of cytoplasmic structures.
Both polyphemusin I (RRWCFRVCYRGFCYRKCR-NH2) and the free C-terminal cysteine derivative polyphemusin (PM1-Cys, RRWCFRVCYRGFCYRKCRC-NH2) were synthesized by the tert-butoxycarbonyl method, folded, and purified at the Peptide Synthesis Facility, Biomedical Research Centre, University of British Columbia. Correct disulfide bond formation (between cysteine residues 4 to 17 and 8 to 13) of the purified peptides was confirmed by matrix-assisted laser desorption ionization mass spectrometry and further verified by circular dichroism (CD) spectroscopy (data not shown). PM1-Cys was labeled with biotin by use of N
-(3-maleimidylpropionyl)biocytin and the method recommended by Molecular Probes (Eugene, OR). The resulting PM1-biotin was purified by reverse-phase chromatography and confirmed by matrix-assisted laser desorption ionization mass spectrometry and was found to have the expected molecular weight of 3,079 (data not shown). In addition, the biotin label did not affect the overall structure of polyphemusin I, as the CD spectra of labeled and unlabeled peptide in Tris buffer were nearly identical (data not shown).
To determine the influence of biotinylation on the antimicrobial activity of polyphemusin I, MICs were determined using the broth microdilution method with Mueller-Hinton medium (Difco Labs, Detroit, MI) (7); the MIC was defined as the lowest peptide concentration at which no growth was observed after an overnight incubation at 37°C. MIC assays were performed three separate times, and the mode values were recorded. The MIC of polyphemusin I against wild-type E. coli UB1005 was found to be 0.25 µM (0.6 µg/ml), which is similar to previously published values (6), and the MIC of PM1-biotin was twofold greater at 0.5 µM (1.5 µg/ml), indicating that the addition of biotin had a minimal effect on the MIC.
To further characterize the antimicrobial activity of PM1-biotin, killing curves were performed to determine the kinetics of killing. Killing curves, at peptide concentrations 10-fold higher than the MIC, were performed using E. coli UB1005, as previously described (10). A representative trial from three independent experiments is shown (Fig. 1). Complete killing by polyphemusin I was observed within 5 min, consistent with previous studies (10). PM1-biotin showed similar killing kinetics but incomplete killing at the concentration tested (5 µM, or approximately 10x MIC); however, a 99.9% reduction in the number of viable cells indicated that the peptide retained substantial antimicrobial activity.
![]() View larger version (15K): [in a new window] |
FIG. 1. Killing of E. coli UB1005 by polyphemusin I (triangles) and PM1-biotin (circles). Killing curves were performed at 10x peptide MIC and represent results from one experiment of three that demonstrated similar trends. A non-peptide-treated control experiment (squares) was also performed.
|
![]() View larger version (7K): [in a new window] |
FIG. 2. Fluorescence microscopy of E. coli UB1005 treated with PM1-biotin. Bacteria were incubated at 4°C (top panels) or 37°C (bottom panels) without peptide (A and D) and at peptide concentrations of one-half MIC (B and E) and 4x MIC (C and F) for 30 min. Blue fluorescence staining represents intracellular DAPI-stained DNA, while green fluorescence staining represents the Alexa Fluor-labeled peptide.
|
As a control, E. coli cells were treated with PM1-biotin at 4°C. At this temperature, membrane translocation was prevented due to the rigid state of the lipids in both inner and outer membrane bilayers. Figures 2B and C confirmed this choice as a control, as intracellular peptide fluorescence was not observed and a clear delineation of the bacterium due to membrane-bound peptide was observed. These observations agreed with previous studies and supported the view that polyphemusin I does not cause pore formation or significant membrane damage (9, 10).
To more precisely determine the localization of polyphemusin, confocal microscopy was performed with the same E. coli samples treated at one-half-MIC PM1-biotin, as described above (Fig. 3). Control samples incubated with peptide at 4°C (Fig. 3A) appeared as hollow rods, with fluorescence clearly defining the bacterial surface membranes. Intracellular fluorescence was not observed, indicating that peptide membrane translocation did not occur. Conversely, E. coli samples treated with peptide at 37°C (Fig. 3B) appeared as solid fluorescent rods, indicating the presence of peptide within the cytoplasm. This is consistent with studies demonstrating that polyphemusin I can translocate across liposome membranes and even at twofold MIC is only able to depolarize by 50% the E. coli cytoplasmic membrane (i.e., make it partly leaky to protons) (6).
![]() View larger version (62K): [in a new window] |
FIG. 3. Confocal microscopy of E. coli UB1005 treated with PM1-biotin. Bacteria were incubated with peptide at 4°C (A and C) or 37°C (B and D) at one-half MIC for 30 min. Prior to fluorescence labeling, cells were treated (A and B) or not treated (C and D) with 0.2% Triton X-100.
|
The data presented here demonstrate for the first time membrane translocation of a polyphemusin I analogue, PM1-biotin, in intact bacterial cells. This finding agrees with previously published translocation studies using model membranes (6, 9). In addition, the absence of cytoplasmic fluorescence in cells treated with peptide but not permeabilized with Triton X-100 indicated that PM1-biotin did not induce significant membrane damage or pore formation. These findings confirmed our hypothesis that polyphemusin is capable of translocating membranes and does not cause major membrane damage allowing the entry or leakage of molecules into or out of cells.
We acknowledge Phil Owen at the Peptide Synthesis Facility, Biomedical Research Centre, University of British Columbia, for peptide synthesis and purification and mass spectrometry of biotin-labeled peptide, Fred Rosell at the UBC Laboratory of Molecular Biophysics for the use of and assistance with their CD spectropolarimeter, and Joseph McPhee for critical discussions.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»